A Phase 3 interventional study of Lisdexamfetamine Dimesylate and Atomoxetine Hydrochloride in Attention-Deficit/Hyperactivity Disorder, sponsored by Shire. Completed at 64 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-11.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 12th largest by enrollment, is one of 5 that started in 2010, is one of 15 in phase 3, and was the 27th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:
Medical University of Lodz · Sites in Poland
Ages 8 yrs–198 mo
By country, each count listing its studies:
lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 15 · Phase 4 23
First in 2004; this study’s year is marked. 5 started in 2010.
This study's enrollment of 267 is above the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 48 across the 51 interventional studies. Of the 49 that completed or were terminated, 37 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
57 studies in Attention Deficit Disorder with Hyperactivity by Takeda: none open now, none under way, none of them phase 3. Of 55 finished, 37 (67%) have results posted.
Among the 57 studies in Attention Deficit Disorder with Hyperactivity by Takeda, this one is the 24th largest by enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2010, is one of 32 in phase 3, and was the 35th registered.
Takeda’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 57 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate how long it takes for ADHD symptoms to improve in subjects who are judged by the Investigator to have had an inadequate response to methylphenidate therapy. The study will also test the safety of Lisdexamfetamine Dimesylate and how well it works.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lisdexamfetamine Dimesylate
Drug: Atomoxetine Hydrochloride
Oral 30, 50, or 70mg once-daily for 9 weeks
Also known as: Vyvanse
Oral 10mg to 100mg once-daily for 9 weeks
Also known as: Strattera
Time to First Response
Time to first response was defined as a Clinical Global Impression-Improvement (CGI-I) value of 1 (very much improved) or 2 (much improved) first recorded following first dose of investigational product. CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: 9 weeks
Percent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores - Last Observation Carried Forward (LOCF)
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
Time frame: 9 weeks
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at 9 Weeks - LOCF
ADHD-RS-IV consists of 18 items scored on a 4-point scale from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.
Time frame: Baseline and 9 weeks
Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Up to 9 Weeks
The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.
Time frame: Baseline and up to 9 weeks
Health Utilities Index-2 (HUI-2) Scores at Up to 9 Weeks
HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.
Time frame: up to 9 weeks
Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Up to 9 Weeks
The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.
Time frame: Baseline and up to 9 weeks
Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
Time frame: 9 weeks
Udvalg for Kliniske Undersogelser Side Effect Rating Scale - Clinician (UKU-SERS-Clin) With Side Effects Scores >=1
UKU-SERS-Clin is composed of 48 items each of which asks about a single side effect. Each side effect is rated based on a 4-point scale ranging from 0 (no or doubtful presence) to 3 (the least favorable rating). The rating is independent of whether the symptom is regarded as related to the investigational product.
Time frame: 9 weeks
| Milestone | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride |
|---|---|---|
| Started | 133 | 134 |
| Completed | 100 | 101 |
| Not completed | 33 | 33 |
| Withdrew: Adverse event | 8 | 10 |
| Withdrew: Lack of efficacy | 2 | 13 |
| Withdrew: Lost to follow-up | 5 | 1 |
| Withdrew: Early termination requested by sponsor | 1 | 0 |
| Withdrew: Moved out of state | 0 | 1 |
| Withdrew: Refused to take medication | 0 | 1 |
| Withdrew: Noncompliance | 0 | 1 |
| Withdrew: Hard time swallowing the pills | 1 | 0 |
| Withdrew: Previous use of marijuana | 1 | 0 |
| Withdrew: Protocol violation | 7 | 2 |
| Withdrew: Withdrawal by subject | 8 | 4 |
Time to first response was defined as a Clinical Global Impression-Improvement (CGI-I) value of 1 (very much improved) or 2 (much improved) first recorded following first dose of investigational product. CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
| Days | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride |
|---|---|---|
| Time to First Response | 12.0 (8.0 to 16.0) | 21.0 (15.0 to 23.0) |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.
| percentage of participants | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride |
|---|---|---|
| Percent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores - Last Observation Carried Forward (LOCF) | 81.7 | 63.6 |
ADHD-RS-IV consists of 18 items scored on a 4-point scale from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.
| units on a scale | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride |
|---|---|---|
| Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at 9 Weeks - LOCF | -26.1 ± 1.16 | -19.7 ± 1.13 |
The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.
| units on a scale | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride |
|---|---|---|
| Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Up to 9 Weeks | -0.35 ± 0.034 | -0.27 ± 0.032 |
HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.
| units on a scale | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride |
|---|---|---|
| Health Utilities Index-2 (HUI-2) Scores at Up to 9 Weeks | 0.920 ± 0.0961 | 0.922 ± 0.0937 |
The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.
| units on a scale | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride |
|---|---|---|
| Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Up to 9 Weeks | -10.7 ± 9.27 | -7.9 ± 9.07 |
C-SSRS is a semi-structured interview that captures the occurence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behaviour occurred. The assessment is done by the nature of the responses, not by a numbered scale.
| participants | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride |
|---|---|---|
| Suicidal ideation | 0 | 0 |
| Suicidal behavior | 0 | 0 |
UKU-SERS-Clin is composed of 48 items each of which asks about a single side effect. Each side effect is rated based on a 4-point scale ranging from 0 (no or doubtful presence) to 3 (the least favorable rating). The rating is independent of whether the symptom is regarded as related to the investigational product.
| participants | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride |
|---|---|---|
| Weight Loss | 46 | 19 |
| Reduced Duration of Sleep | 29 | 16 |
| Asthenia/Lassitude/Increased Fatigability | 25 | 29 |
| Tension/Inner Unrest | 20 | 22 |
| Nausea/Vomiting | 19 | 26 |
| Sleepiness/Sedation | 16 | 35 |
| Reduced Salivation | 16 | 6 |
| Headache-Tension Headache | 15 | 17 |
| Concentration Difficulties | 75 | 92 |
| Failing Memory | 10 | 21 |
| Depression | 6 | 10 |
| Increased Duration of Sleep | 12 | 12 |
| Increased Dream Activity | 3 | 8 |
| Emotional Indifference | 12 | 10 |
| Dystonia | 0 | 1 |
| Rigidity | 0 | 1 |
| Hypokinesia/Akinesia | 1 | 0 |
| Hyperkinesia Logic | 2 | 3 |
| Tremor | 3 | 1 |
| Akathisia | 0 | 2 |
| Paraesthesias | 1 | 0 |
| Accomodation Disturbances | 0 | 2 |
| Increased Salivation | 1 | 2 |
| Diarrhea | 6 | 9 |
| Constipation | 9 | 5 |
| Micturition Disturbances | 0 | 1 |
| Polyuria/Polydipsia | 3 | 2 |
| Orthostatic Dizziness | 10 | 9 |
| Palpitations/Tachycardia | 1 | 5 |
| Increased Tendency to Sweating | 3 | 5 |
| Rash-Morbiliform | 0 | 1 |
| Rash-Petechial | 1 | 0 |
| Rash-Urticarial | 1 | 1 |
| Rash-Cannot be Classified | 1 | 2 |
| Pruritus | 4 | 7 |
| Weight Gain | 1 | 0 |
| Headache-Migraine | 2 | 2 |
| Headache-Other Forms | 11 | 10 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lisdexamfetamine Dimesylate | — | 0/128 (0%) | 92/128 (71.9%) |
| Atomoxetine Hydrochloride | — | 0/134 (0%) | 95/134 (70.9%) |
| Event | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride |
|---|---|---|
| DECREASED APPETITEMetabolism and nutrition disorders | 33/128 | 14/134 |
| WEIGHT DECREASEDInvestigations | 28/128 | 9/134 |
| HEADACHENervous system disorders | 17/128 | 22/134 |
| NAUSEAGastrointestinal disorders | 16/128 | 21/134 |
| SOMNOLENCENervous system disorders | 4/128 | 16/134 |
| INSOMNIAPsychiatric disorders | 15/128 | 8/134 |
| FATIGUEGeneral disorders | 12/128 | 14/134 |
| VOMITINGGastrointestinal disorders | 6/128 | 13/134 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 3/128 | 10/134 |
| DIARRHOEAGastrointestinal disorders | 2/128 | 9/134 |
Safety Population was used for baseline characteristics (n = 262). Defined as all subjects who were randomized and who had taken at least 1 dose of investigational product. Five randomized subjects did not take any investigational product.
| Age, Continuous(Years) | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride | Total |
|---|---|---|---|
| Mean | 10.9 ± 3.01 | 10.4 ± 2.84 | 10.6 ± 2.93 |
| Age, Customized(Participants) | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride | Total |
|---|---|---|---|
| 13 - 17 years | 34 | 34 | 68 |
| 6 - 12 years | 94 | 100 | 194 |
| Sex: Female, Male(Participants) | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride | Total |
|---|---|---|---|
| Female | 34 | 31 | 65 |
| Male | 94 | 103 | 197 |
| Region of Enrollment(Participants) | Lisdexamfetamine Dimesylate | Atomoxetine Hydrochloride | Total |
|---|---|---|---|
| BELGIUM | 0 | 2 | 2 |
| CANADA | 17 | 18 | 35 |
| GERMANY | 20 | 22 | 42 |
| HUNGARY | 10 | 10 | 20 |
| ITALY | 1 | 0 | 1 |
| POLAND | 0 | 1 | 1 |
| SPAIN | 12 | 10 | 22 |
| SWEDEN | 3 | 3 | 6 |
| UNITED STATES | 70 | 68 | 138 |
Ran from Jun 2010 to primary completion in Jul 2012, 24 months.
Results were first posted in Jun 2013, 11 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 24 months is above that.
Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lisdexamfetamine
Attention Deficit Disorder with Hyperactivity →